LXEO · Lexeo Therapeutics, Inc. · Executive Compensation
Market Cap
$348.70M
Shares
82.05M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| R. Nolan Townsend | Chief Executive Officer and Director | $3,650,940 |
| Jenny R. Robertson | Former Chief Legal Officer | $2,145,883 |
| Louis Tamayo | Chief Financial Officer | $1,665,915 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| R. Nolan Townsend | Chief Executive Officer and Director | $4,375,248 |
| Jose Manuel Otero | Chief Technical Officer | $3,555,468 |
| Eric Adler | Chief Medical Officer and Head of Research | $3,162,534 |
| Jenny R. Robertson | Former Chief Legal Officer | $2,485,110 |
| Louis Tamayo | Chief Financial Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Eric Adler | Chief Medical Officer and Head of Research | $3,042,824 |
| R. Nolan Townsend | Chief Executive Officer and Director | $1,737,218 |
| Jose Manuel Otero | Chief Technical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Laura Sepp-Lorenzino | director | Appointed | 2026-04-30 |
| Narinder P. Bhalla, M.D. | Chief Medical Officer | Appointed | 2026-01-27 |
| Jose Manuel Otero, Ph.D. | Chief Operating Officer | Appointed | 2026-01-27 |
| Kyle Rasbach | Chief Financial Officer | Resigned | 2025-08-14 |
| Louis Tamayo | Chief Financial Officer | Appointed | 2025-08-14 |
| Kyle Rasbach | Chief Financial Officer | Appointed | 2024-12-19 |
| Tolga Tanguler | director | Appointed | 2024-11-13 |
Key facts
CIK
1907108
CUSIP
52886X107
13F (30d)
55 filings
55 filers
Visit website
Investor relations